Ipca Labs Q2 Review - Temporary Margin Hiccup; Revenue Drivers Intact: Yes Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Yes Securities Research Report.Ipca Laboratories Ltd.'s domestic business continues to exhibit robust strength though exports formulations were largely affected with all segments falling sequentially after a strong Q1. Ipca Labs' active pharma ingredients business was disrupted majorly due to sartan issue which is expected to be resolved by Q4 FY22. Q3 is expected to be underwhelming with pressures on revenues as well as margin front. Albeit, domestic business is trending better than guidance and reckon it would cushion some of the input cost pressures and export revenue led weakness in H2. Overall, we believe cost pressure led weakness in margin is relatively quick to resolve (through price hikes if it lasts longer or, as is expected, raw material costs cool off) rather than any sluggishness emanating from slower revenue growth..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Ipca Labs Q2 Review - Temporary Margin Hiccup; Revenue Drivers Intact: Yes Securities

Ipca Labs Q2 Review - Temporary Margin Hiccup; Revenue Drivers Intact: Yes Securities

Choose a plan